



(11) **EP 2 575 795 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(51) Int Cl.:
A61K 31/05 ^(2006.01) **A61K 31/085** ^(2006.01)
A61K 31/202 ^(2006.01) **A61K 31/355** ^(2006.01)
A61K 31/375 ^(2006.01) **A61K 36/53** ^(2006.01)
A61P 17/02 ^(2006.01)

(48) Corrigendum issued on:
23.10.2019 Bulletin 2019/43

(86) International application number:
PCT/IB2011/001113

(45) Date of publication and mention
of the grant of the patent:
04.09.2019 Bulletin 2019/36

(87) International publication number:
WO 2011/148247 (01.12.2011 Gazette 2011/48)

(21) Application number: **11730740.5**

(22) Date of filing: **24.05.2011**

(54) **STABILIZED FORMULATION COMPRISING OMEGA-3 FATTY ACIDS AND USE OF THE FATTY ACIDS FOR SKIN CARE AND/OR WOUND CARE**

STABILISIERTE ZUBEREITUNG ENHALTEND OMEGA-3 FETTSÄUREN UND IHRE
VERWENDUNG ZUR HAUTPFLEGE UND/ODER WUNDVERSORGUNG

COMPOSITION STABILISÉ CONTENANT D' ACIDE GRAS OMEGA-3 ET SA UTILISATION EN SOIN
CUTANÉ ET/OU EN SOIN DE PLAIE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **26.05.2010 US 348357 P**

(43) Date of publication of application:
10.04.2013 Bulletin 2013/15

(60) Divisional application:
19193607.9

(73) Proprietor: **Kerecis EHF**
113 Reykjavik (IS)

(72) Inventors:
• **SIGURJONSSON, Gudmundur Fertram**
IS-101 Reykjavik (IS)
• **LLIEVSKA, Biljana**
IS-400 Isafjordur (IS)

• **BALDURSSON, Baldur Tumi**
IS-105 Reykjavik (IS)

(74) Representative: **Klunker IP**
Patentanwälte PartG mbB
Destouchesstraße 68
80796 München (DE)

(56) References cited:
EP-A1- 0 699 437 EP-A1- 1 637 130
WO-A1-00/49889 WO-A1-2011/057183
GB-A- 2 458 466 GR-B1- 1 004 395
US-A1- 2007 243 307

• **KARIN ENGSTRÖM ET AL: "Effect of fish oils
containing different amounts of EPA, DHA, and
antioxidants on plasma and brain fatty acids and
brain nitric oxide synthase activity in rats",
UPSALA JOURNAL OF MEDICAL SCIENCES, vol.
114, no. 4, 1 December 2009 (2009-12-01), pages
206-213, XP55005475, ISSN: 0300-9734, DOI:
10.3109/03009730903268958**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 575 795 B8